An association between oncogenic transformation and repression of different components of the MHC class I antigen processing machinery (APM) have been described in murine model systems. In order to discover whether a similar correlation exists, human tumor cell lines of distinct histology with altered ras protein were analyzed for the expression of APM components utilizing RT-PCR and Western blot analyses. A heterogeneous expression pattern of MHC class I antigens, TAP peptide transporter, proteasome subunits, proteasome activator PA28 and the chaperones calnexin, calreticulin as well as tapasin was displayed by these tumor cell lines. Single or combined deficiencies in the expression and/or function of TAP, LMP2, LMP10 and tapasin were demonstrated in 11 of 12 cell lines studied, whereas the expression of calnexin, calreticulin, ␤ 2 -microglobulin, LMP7 and PA28␣ was unaltered or only weakly decreased. The impaired expression of TAP, LMP subunits and tapasin was not associated with altered ras, but resulted in reduced MHC class I surface expression. In particular, a significant allele-and locusspecific downregulation of the HLA-A and HLA-B haplotypes was found. IFN-␥ treatment corrected the TAP, LMP and tapasin deficiencies and enhanced the constitutive PA28␣, LMP7, calnexin and calreticulin expression which was accompanied with increased levels of MHC class I antigens. Thus, dysregulation rather than structural alterations of different APM components might be one mechanism of colon carcinoma, small cell lung carcinoma and pancreatic carcinoma cell lines to evade immune recognition. Bone Marrow Transplantation (2000) 25, Suppl. 2, S88-S95.
expressed ␤ subunits X, Y and Z of the proteasome 3, 4 are replaced by the IFN-␥ regulated subunits LMP2, LMP7 and LMP10, 4, 5 thereby altering the proteolytic production of certain peptides. 6 In addition, the binding of the proteasome activator PA28 to the proteasome also influences both the quality and quantity of peptides. 6 The yielded peptides are translocated across the endoplasmic reticulum (ER) membrane via the heterodimeric complex consisting of the ATPdependent transporter associated with antigen processing genes, TAP1 and TAP2. 7, 8 In the ER, the peptides bind to the MHC class I molecules and the ternary complex is exported through the secretory pathway to the cell membrane.
The assembly of the MHC class I heavy chain with ␤ 2 -microglobulin (␤ 2 -m) and peptide is assisted by transient interactions with a number of ER-resident chaperones, such as calnexin, calreticulin, protein disulfide isomerase and the newly identified glycoprotein tapasin. 9 The heterodimer aggregates with TAP and forms a 'large TAP complex' consisting of TAP1, TAP2, MHC class I heavy and light chains, calreticulin and tapasin. 10, 11 Tapasin is bridging TAP and MHC class I molecules thereby playing a critical role in the MHC class I assembly. Binding of high affinity peptides to MHC class I molecules leads to the dissociation of this 'large TAP complex' and the exit of the ternary MHC class I molecules from the ER. 11 Studies on mutant cell lines or on knock out mice have been extremely useful in defining the role of the different components of the MHC class I antigen processing and presentation pathways. [12] [13] [14] Although TAP and LMP subunits are not absolutely required for MHC class I antigen presentation, 12, 15, 16 their deficient expression often results in reduced levels of MHC class I surface molecules and impaired MHC class I restricted T cell responses. 13, 15, 16 Loss or reduced expression of MHC class I molecules is a frequent event in human tumors of different histology and has been attributed to structural alterations and/or dysregulation of various components of the MHC class I antigen processing machinery (APM). [17] [18] [19] A number of studies demonstrated a coordinated TAP and LMP downregulation, but deficiencies in a single APM component have also been described. [19] [20] [21] In a murine model of oncogenic transformation, reduced MHC class I surface expression was inversely associated with mutated ras oncogene expression due to suppression of TAP1 and LMP2. 22 The expression pattern of the different APM components has not been analyzed in detail in human tumors with mutant ras. Therefore, we examine the constitutive and interferon (IFN)-␥ regulated expression of various chaperones, TAP, different proteasome subunits and MHC class I antigens in small cell lung carcinoma (SCLC), pancreatic carcinoma and colon carcinoma cell lines.
Materials and methods

Cell lines, cell culture and IFN-␥ treatment
With the exception of Panc1 and Stom1 the human tumor cell lines of distinct histology employed in this study were obtained from the American Tissue Type Culture Collection (Rockville, MD, USA). The HLA phenotype of the different cell lines, kindly provided by E Hilmes (Johannes Gutenberg-University, Blood Bank) was determined by genomic polymerase chain reaction (PCR) using the Dynal SSP primer system (Dynal, Hamburg, Germany). All tumor cell lines were grown in Dulbecco's medium (Biochrom, Berlin, Germany) supplemented with 10% fetal calf serum (FCS) (Greiner, Frickenhausen, Germany), 2 mm glutamine, penicillin and streptomycin. The human lymphoblastoid cell line T1 and its mutant derivative T2 23 encompassing deletions of the TAP1/2 and LMP2/7 genes, were maintained in CRPMI (Biochrom) completed with 10% FCS, glutamine and respective antibiotics and served as controls.
Cells were treated with human recombinant 50 g/ml IFN-␥ (specific activity of 3 ϫ 10 6 U/mg protein) kindly provided by Thomae (Biberach, Germany) for the indicated length of time.
Primers, RT-PCR analysis and sequencing
The oligonucleotides used for PCR analysis, sequencing and hybridizations were generated by employing the Primer Designer program (Version 2.01; Scientific & Educational Software), synthesized by the triester method and purchased from MWG Biotech (Ebersberg, Germany). The primers and the PCR conditions used are listed in Table 1 . Total cellular RNA from 5 ϫ 10 7 cells was isolated by the guanidinium isothiocyanate method and subjected to onestep RT-PCR analysis (Titan Kit; Roche Diagnostics, Mannheim, Germany) as recently described. 24 In most cases, ␤-actin and APM specific PCR was performed in the same reaction using 10 cycles of 20 s at 94°C at the annealing temperature, 1 min at 68°C followed by 25 cycles of 1 min at 94°C, 1 min at the annealing temperature, 1 min at 68°C with a cycle elongation of 5 s for each cycle.
The amplification products were size fractionated on a 1% agarose gel and the specificity of analysis was confirmed by determination of the predicted size as well as by Southern blotting of the gels followed by processing of filters with digoxygenin (DIG)-labeled specific oligonucleotides using the DIG chemiluminescence detection kit (Roche Diagnostics). Gene expression was quantitated by densitometric analysis of the autoradiograms and normalized to the ␤-actin signal. Mutations of the ras oncogene were evaluated by directly sequencing the PCR products. 24 
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Immunofluorescence analysis
Immunofluorescence analysis was performed using the following monoclonal antibodies (mAb): MsIgG (negative control; Coulter-Beckman, Krefeld, Germany), the hybridoma supernatant of W6/32 recognizing HLA-A, -B, -C locus products complexed to ␤ 2 -m, the locus-specific mAb HLA-A and HLA-B kindly provided by Dr S Ferrone (Valhalla, USA), the allele-specific mAb recognizing HLA-A1, HLA-B7 and HLA-A2.1 (BB7.2), mAb 148.3 recognizing TAP1, and BBM1, which was kindly provided by E Weiss (Institute of Human Genetics, München, Germany), recognizing free and complexed ␤ 2 -m. The second antibody was FITC-labeled goat anti-mouse antibody (CoulterBeckman).
Prior to staining with the mAb 148.3 directed against TAP1, cells were permeabilized with 70% ethanol for 30 min on ice. For cytofluometry, 5 ϫ 10 5 to 1 ϫ 10 6 cells were incubated for 30 min at 4°C with an excess of the respective antibody, washed twice with PBS, incubated with FITC-GAM for an additional 30 min at 4°C before being analyzed on a flow cytometer (Coulter EPICS XL, MCL, Coulter-Beckman).
Peptide synthesis and peptide binding analysis
The following peptides synthesized on solid phase using Fmoc for transient NH 2 -terminal protection and characterized by amino acid analysis were employed in peptide binding assays: the HLA-A2 binding HIV peptide C7 (HIV pol 510-518; ILKEPVHGV) and the H-2 binding CMV peptide A7 (YPHFMPTNL). Briefly, 5 ϫ 10 5 cells were incubated for 15 to 18 h in serum-free medium in the presence or absence of 100 m peptide with or without 2.5 g/ml human ␤ 2 -m (Sigma, St Louis, MO, USA). Peptide-labeled cells were stained by indirect immunofluorescence analysis as described. 20 
Peptide translocation assay
For peptide translocation, 2.5 ϫ 10 6 cells/incubation were harvested and washed once with incubation buffer (130 mm KCl, 10 mm NaCl, 1 mm CaCl 2 , 2 mm EGTA, 2 mm MgCl 2 , 5 mm Hepes, pH 7.3). 25 Cells were permeabilized with 2 IU streptolysin O/ml (Welcome Reagent, Beckenham, UK) in 50 l incubation buffer for 10 min at 37°C followed by the addition of 10 l ATP (10 mm; Roche Diagnostics), 10 l radioiodinated peptide and additional incubation buffer to a final volume of 100 l. Peptide translocation was inhibited by lysing the permeabilized cells with 1 ml NP-40 lysis mix. Glycosylated peptides were recovered with ConA-Sepharose (Pharmacia, Uppsala, Sweden) as described.
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Results
Reduced expression of MHC class I antigen processing genes in human tumors of epithelial origin is not associated with ras mutations
In order to evaluate whether a relationship between ras mutations/overexpression and suppression of the MHC class I antigen processing pathway exists, the ras phenotype of 12 human tumor cell lines of distinct origin was analyzed (Table 2 ). Seven out of 12 tumor cell lines possessed a mutation in codon 12;13 of the Ki-ras gene resulting in an amino acid (aa) change from glycin to asparagin, arginin, valin or serin, respectively. No structural alterations were found in the Ki-ras codon 61 and in the mutation hot spots of the N-ras gene of these tumor cells (data not shown).
The mRNA expression of APM components in the tumor cell lines with variable ras phenotype as well as T1 cells and pbmnc encompassing normal expression or characterized deficiencies (T2 cells) was analyzed by RT-PCR using ␤-actin primers as the internal standard. Deficient or reduced expression of certain genes was found in a high percentage of colon, SCLC and pancreatic tumor cell lines ( Table 3 , Figure 1 ), whereas others are only marginally suppressed or are even unaltered. Calnexin and calreticulin were expressed in all tumor cell lines and the level of expression was similar to that of T1 cells, whereas tapasin expression was only strongly decreased in the SCLC cell line Colo 699. Thus, alterations in the constitutive chaperone expression were limited to tapasin and only to a minority of tumor lines. In addition, LMP7 and ␤ 2 -m transcription was not altered in any tumor cell line tested. With the exception of Colo 699 cells, PA28␣ transcription was comparable in all tumor cell lines to that of respective control cells. The most prominent differences were obtained by analyses of the LMP2, LMP10, TAP1 and TAP2 transcription. Five out of 12 tumor cell lines displayed impaired TAP1 S91 Table 3 Heterogeneous expression pattern of antigen processing genes in tumor cells of distinct origin and LMP2 expression, TAP2 was suppressed in 9/12 tumor cell lines and LMP10 in 2/12 tumor cell lines. In Stom and CX1 cells, the expression of TAP1, TAP2 and LMP2 was coordinately downregulated. A simultaneous suppression of TAP1 and LMP2 transcription was found in CX1 and A549
Bone Marrow Transplantation (Table 3 ; Figure 1 ). However, a relationship between downregulation of TAP/LMP and ras mutations did not exist.
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Decreased expression of peptide transporters is associated with impaired function but not with the ras phenotype
In order to analyze whether reduced TAP transcription affects TAP activity, peptide translocation assays were performed in the presence and absence of ATP utilizing two different input peptides. Representative results with the peptides #600 (TNKTRIDGQY) and #63 (RYWANATRSI) demonstrated an ATP-dependent peptide transport (data not shown) which is highly variable in the different tumor cell lines analyzed (Figure 2 ). The transport of peptide #600 was in most cases more effective than that of peptide #63 ranging from 0.4% (negative) to more than 14% in the pancreatic carcinoma cell line ASCP1 and the SCLC line A549. TAP activity was totally abrogated with a transport rate for both peptides of 0.4 to 0.6% in CX1 cells, which was comparable to that of TAP-deficient T2 cells (data not shown).
Locus-specific downregulation of MHC class I surface expression in human epithelial tumor cell lines
MHC class I surface expression of the various tumor cell lines was determined by flow cytometry using a mAb (W6/32) recognizing human HLA class I antigens, the locus-specific mAb HLA-A and HLA-B as well as the allele-specific mAb HLA-B7 and mA2.1 recognizing HLA-A2. Staining with mAb W6/32 revealed a significantly reduced MHC class I surface expression in pancreatic, colon and small cell lung carcinoma cell lines when compared to the lymphoblastoid T1 cells (Table 2 ). DLD1 cells even totally lack MHC class I surface expression. Representative results were shown for Colo 699, CX1 and Colo 206F cells (Figure 3 ), further demonstrating a strong HLA-A and HLA-B locus and/or allele-specific downregulation when compared to total MHC class I surface expression. 
MHC class I surface molecules in APM-deficient tumor cell lines could not be stabilized at physiological temperature or by MHC class I binding peptides
MHC class I surface expression of APM-defective cells can be stabilized both by culture at low temperature or by the addition of specific HLA-binding peptides. 26 Peptide binding assays were performed with the specific HLA-A2 binding HIV peptide and the nonsense H-2 binding CMV peptide as negative control. Incubation with the HLA-A2-specific binding peptide also did not influence the level of MHC class I surface expression in HLA-A2ϩ tumor cells (Figure 4, upper panel) , whereas MHC class I expression of T2 cells was three-fold increased. As expected, the CMV control peptide did not affect MHC class I surface expression. These results were further confirmed by temperature assays. The cell lines were in parallel maintained for 36 h at 26°C or 37°C before MHC class I surface expression was determined. T1 cells and their APMdeficient mutant T2 served as controls. MHC class I expression was not enhanced by incubation tumor cells and T1 cells at low temperature, whereas enhancement of MHC class I surface expression was observed on mutant T2 cells ( Figure 4 , lower panel), suggesting that deficient expression and function of APM genes is only partially responsible for lack or reduced MHC class I surface expression of the tumor cell lines analyzed.
Treatment with IFN-␥ caused reversion of most antigen processing deficiencies
IFN-␥ is known to induce the expression of most components of the antigen processing pathway such as TAP, LMP, PA28 and MHC class I molecules. 19, 27 Therefore, the effect of IFN-␥ on the described APM deficiencies in colon, pancreatic, stomach and lung carcinoma cells was determined. IFN-␥ treatment of these tumor cell lines results in an approximately two-fold induction of the mRNA expression of all APM components, including HLA class I antigens, TAP, LMP, PA28␣, the chaperones tapasin, calnexin and calreticulin ( Figure 1 and Table 3 ), which was also associated with increased TAP activity and enhanced total, locus-and allele-specific MHC class I surface expression (Figure 3) . Thus, the deficiencies in the antigen processing pathway could be reverted by cytokine treatment and therefore seemed to be due to dysregulation rather than structural alterations.
Discussion
There exists strong evidence that one major immune escape mechanism of tumors of different histology, such as SCLC, renal cell carcinoma, cervical carcinoma, colon cancer and melanoma is the impaired expression and function of different APM components, particularly TAP1, TAP2, LMP2 and LMP7, all located within the MHC class II region. 19, 20 Recently, Johnssen and coauthors 21 extended these analyses to the proteasome subunits LMP10, PA28␣ and PA28␤ known to be involved in the antigen processing, but encoded outside of the MHC class II locus. In this study, 30%
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Our experiments evaluated a panel of human tumor cell lines of different histology with distinct ras phenotypes for the expression pattern of TAP, LMP subunits, PA28, calnexin, calreticulin and tapasin. Deficiencies in the expression of single or multiple APM component(s) were detected in 11 out of 12 tumor cell lines tested. The defects observed in the tumor cell lines studied did not affect all TAP and LMP genes clustered in the MHC class II region. A simultaneous suppression was not even obtained in all cases for TAP1 and LMP2, which are regulated by a shared bidirectional promoter. 28 However, heterogeneous TAP transcription was directly associated with its function (Figure 2 ), but the observed differences in the transport rate of peptide #600 and #63 cannot be explained yet, although Neefjes and coauthors demonstrated variable transport efficiencies depending on the peptide employed. 29 An important role in effective antigen processing was implicated for chaperones. For example, tapasin-defective cells lack MHC class I surface expression, which could be reconstituted by tapasin gene transfer. 14 The analysis of chaperone transcription demonstrated that calnexin and calreticulin expression was unaltered, but constitutive tapasin expression was reduced in the SCLC cell line Colo 699, also expressing low levels of MHC class I surface antigens. Thus, impaired tapasin expression occurs only in a minority of tumors but may play an important role for immune escape ( Figure 1, Table 3 ). However, to further evaluate its importance, more tumors have to be monitored.
In previous studies, an in vitro model of ras transformed murine fibroblasts demonstrated that ras expression was inversely associated with impaired MHC class I surface expression due to TAP1 and LMP2 downregulation. 22 Until now, limited information has been available whether altered ras expression in human tumor cells affects MHC class I as well as APM gene expression, thereby resulting in reduced sensitivity to CTL-mediated lysis. Our results argue against a direct correlation between ras mutations and APM deficiencies, since single or combined APM defects were observed in colon, pancreatic and SCLC tumor cells both in the presence and absence of ras mutations (Table 2; Figure 1 ). However, these data have to be extended to a larger number of tumor cell lines and to in vivo tumor lesions. In addition, the relatively frequent loss of MHC class I molecules and TAP1 in lung cancer has to be reevaluated concerning the ras phenotype of the APMdefective tumor specimen. 19, 30 The observed impaired APM expression could mainly be ameliorated by IFN-␥ treatment suggesting that the deficient expression is due to dysregulation. The constitutive expression pattern of PA28␣ calnexin and calreticulin is relatively conserved in tumor cells in comparison to TAP, LMP and tapasin. The major role of the latter genes seemed to be the effective generation and transport of antigenic peptides, whereas calnexin, calreticulin and PA28␣ may provide the cell with essential functions independent of the effective antigen processing, although IFN-␥-mediated induction of calnexin and calreticulin not only argues for their general importance for cellular functions, but also for immune responses.
In summary, the immune escape mechanisms of human tumor cells may involve single or combined deficiencies of different APM components, but the hierarchy of these events has still to be elucidated. Further knowledge of the underlying mechanisms of downregulation of APM may be essential for the proper design of individually tailored T cell-mediated immunotherapeutical strategies.
